Sponsors (3)
The bill clarifies and extends FDA oversight of direct-to-consumer drug advertising—likely improving ad transparency and safety—but imposes near-term compliance costs on manufacturers and risks reducing some consumer-directed educational messaging.
Patients (especially those with chronic conditions) and health systems gain more consistent FDA oversight of drug advertising across TV, print, digital, and social media, which should reduce misleading promotions and improve safety and treatment decision-making.
Consumers (including patients with chronic conditions) receive a clear statutory definition of 'direct-to-consumer' drug advertising, improving transparency about which communications are regulated and enabling more predictable enforcement.
Patients with chronic conditions and other consumers could see reduced educational or awareness advertising if enforcement narrows permissible promotional content, limiting public information about treatment options.
Drug manufacturers will face increased compliance costs and operational burdens to change advertising and labeling to meet the statutory definition within 30 days, costs that may be passed on to taxpayers or consumers.
Based on analysis of 2 sections of legislative text.
Adds a federal definition and regulatory treatment that restricts direct-to-consumer promotional advertising of prescription drugs and biologics across TV, radio, print, digital, and social media.
Introduced July 22, 2025 by Jerrold Lewis Nadler · Last progress July 22, 2025
Adds a new rule to the Federal Food, Drug, and Cosmetic Act that defines and restricts direct-to-consumer promotional communications for prescription drugs and biological products across TV, radio, print, digital platforms, and social media. The rule applies to any prescription drug or biologic approved or licensed by the federal government, regardless of when it was approved, and takes effect 30 days after the Act is enacted.